Article
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Journal for immunotherapy of cancer - 1 Feb 2021
Zhou Jian-Guo, Donaubauer Anna-Jasmina, Frey Benjamin, Becker Ina, Rutzner Sandra, Eckstein Markus, Sun Roger, Ma Hu, Schubert Philipp, Schweizer Claudia, Fietkau Rainer, Deutsch Eric, Gaipl Udo, Hecht Markus
Abstract excerpt
BACKGROUND: The predictive power of novel biological markers for treatment response to immune checkpoint inhibitors (ICI) is still not satisfactory for the majority of patients with cancer. One should identify valid predictive markers in the peripheral blood, as this is easily available before and during treatment. The current interim analysis of patients of the ST-ICI cohort therefore focuses on the development...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.